Event Date & Time

Date: October 2, 2025

Time: 8:00 AM (PT), 11:00 AM (ET), 5:00 PM (CET)

Abstract

CAR-T Therapy continues to evolve rapidly, mRNA encoding CAR constructs directly to T cells in the bloodstream, potentially enabling CAR T cell production in the body without the need to isolate and manipulate T cells outside of the patient. This in vivo CAR-T engineering is a game changer and has significantly reduced the time to patient treatment. Join Joseph Brealey to find out more about in vivo CAR-T reprogramming approaches and how multiple analytics is consolidated into a single workflow, saving time and cost without compromising data quality for your CAR therapy research and development.

Learning Objectives

• Advantages over traditional ex vivo CAR T cell therapy

• Strategies for improving quality control of in vivo CAR T therapies

• Streamline your workflow with combine ligand and mRNA cargo characterization to a single run for in vivo CAR delivery vehicle

🔗 Register Now:

Two Roads to In Vivo CAR-T: The Viral versus Lipid Nanoparticle sprint, Who will win the race?

Speaker Bio

Joseph Brealey

Nanoparticles Analytical Scientist

NanoFCM

Joseph Brealey has been a key member of NanoFCM’s research team for three years. With a background in biochemistry, Joseph focuses on the practical analysis of nanoparticles including extracellular vesicles (EVs), lipid nanoparticles (LNPs), and viral vectors, alongside development of novel analytical protocols.